logo-loader
viewInnovaDerma PLC

Director/PDMR Shareholding

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:5.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:11.5pt;font-family:"Arial","sans-serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .ba{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ba{}p.cr{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:14.85pt;line-height:normal}span.cp{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.cs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.cn{font-size:11.0pt;font-family:"Arial","sans-serif"}p.ct{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.cl{font-size:10.0pt;font-family:"Arial","sans-serif"}p.cu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.cj{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"} p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 11.0pt; text-align: center}span.ci{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 12.65pt; margin-bottom: 11.0pt; text-align: center}p.cx{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;text-align:justify;line-height: normal}p.cy{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold}table.da{margin-left:-5.4pt;border-collapse:collapse;border:none}td.bz{width:214.6pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.db{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-autospace: none}span.cc{font-size:10.0pt; font-family:"Arial","sans-serif"} p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal;text-autospace:none}td.by{width:214.6pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.bw{width:214.6pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}span.bx{font-size:10.0pt; font-family:"Arial","sans-serif";color:black}td.bv{width:214.6pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.de{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.bq{font-div: italic; font-weight: bold; line-height: 120%; margin-bottom: 3.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 0cm; text-align: justify}span.br{font-size:11.0pt; line-height:120%;font-family:"Calibri","sans-serif";color:black} table.df{width:450.25pt;margin-left:-10.8pt;border-collapse:collapse}td.bn{width:45.85pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.dg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify}span.bp{font-size:11.0pt;font-family:"Calibri","sans-serif"}td.bm{width:382.8pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.bl{width:45.85pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}p.dh{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.5pt;font-family:"Arial","sans-serif";text-align:justify}td.bk{width:141.8pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bj{width:230.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bi{width:382.8pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.bh{width:141.8pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bg{width:230.2pt;border:none;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.bf{font-size:10.0pt;color:black}h1.bc{margin-top:11.25pt;margin-right:0cm;margin-bottom:.45pt;margin-left: 10.0pt}span.bd{font-size:10.0pt;font-family:"Helvetica Neue","serif"}p.di{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.0pt;text-align:justify} /**/
RNS Number : 2932R
InnovaDerma PLC
27 February 2019
 

LEI: 213800WRAP6W8VDL6B38

 

InnovaDerma PLC

 ("InnovaDerma" or the "Company")

InnovaDerma PLC

Director/PDMR Shareholding

InnovaDerma (LSE: IDP), a UK developer of life sciences, beauty and personal care products, announces, it was notified on 26 February 2019 that Joseph Bayer, Executive Director/Finance Director has purchased 5,000 Ordinary Shares at a price of 86 pence per Ordinary Share (the "Purchase"). 

Following the Purchase, Joseph Bayer personally now holds a total of 28,180 shares.  He also has a separate holding of 93,333 Ordinary Shares held via his Australian Superannuation Fund which Mr Bayer controls. Therefore, Joseph Bayer's total interest in the Company through direct and indirect holdings is 121,513 Ordinary Shares representing approximately 0.84% of the issued share capital of the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Further enquiries

InnovaDerma

Haris Chaudhry/Joe Bayer

 

+61 (0)3 9863 8030

finnCap Ltd

Geoff Nash/Giles Rolls/Kate Bannatyne

Alice Lane - Corporate Broking

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

Shan Shan Willenbrock/Tom Allison

Joe McGregor

 

+ 44 (0)20 7930 0777

[email protected]

 

 

 

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 Joseph Bayer

 

2.               

Reason for the Notification

 

a)

Position/status

Executive Director

 

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

InnovaDerma PLC

 

b)

LEI

213800WRAP6W8VDL6B38

 

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the Financial instrument, type of instrument

€0.10 each ("Ordinary Shares")

Identification code

IDP         GB00BT9PTW34

 

b)

Nature of the transaction

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s)

Volume and Price - 5,000 Ordinary Shares at 86 pence per share

 

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above

 

e)

Date of the transaction

26 February 2019

 

f)

Place of the transaction

London Stock Exchange, Main Market

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUBRARKUAUUAR

Quick facts: InnovaDerma PLC

Price: 74.6

Market: LSE
Market Cap: £10.81 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

InnovaDerma PLC expects more than doubling of pre-tax profit after strong year

InnovaDerma PLC (LON:IDP) executive chairman Haris Chaudhry and CEO Kieran Callan caught up with Proactive London's Andrew Scott to discuss their trading update for the 12 months to 30 June 2019.  The maker of beauty and personal care products said revenues had increased by 21% to...

on 2/7/19